2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains

A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.

Supply chain shake ups and reorganisation

The last year has seen several events shake up the pharmaceutical supply chain. From the acquisition of Catalent by Novo Holdings to legislation such as the BIOSECURE Act, the industry is preparing for continued shifts in attitudes and prospective collaborations for 2025. “It’s fascinating to consider the supply chain reconfiguration aspect of this situation,” comments Aurelio Arias, Director at IQVIA. “Ultimately, this reconfiguration of supply chains raises an important question; do policies like these truly reduce reliance on a single country, or do they merely reshuffle dependencies?”

Building supply chain resiliency remains a consistent topic for the entire pharmaceutical industry, whether through continued nearshoring efforts or through legislations like the BIOSECURE Act. Additionally, increased interest in particular drug products such as GLP-1 agonists will certainly have an effect on how the supply chain will adapt to and meet the demands of consumers and patients.

The role of AI in Pharma 5.0

Another trend the 2025 Pharma Trends Outlook report examines is the future of AI use in the pharmaceutical industry, and the implications of patient-centred care on how AI is used and regulated throughout the pharma supply chain. Pharma 5.0 emphasises the importance of the patient in all stages of the drug development, manufacturing, and commercialisation pipeline, as well as improving communication between patients, doctors, and pharmaceutical companies.

While the reliability of AI technologies is still under question, especially as regulators race to establish protocol regarding AI in drug manufacturing, the pharmaceutical industry is also contending with the potential safety concerns arising from separating ‘good’ data from ‘bad’ data. Catarina Abreu, Head of Nutraceuticals at PIPA LLC, states that “The thing to emphasise is that, to develop a successful AI strategy, you must first have the right data. Understanding why something didn’t work is just as important as knowing what does work. This data helps optimise processes, improve supply chains, and reduce costs. It could even lead to better energy management, resource allocation, and time efficiency.” Regulatory focuses for the pharmaceutical industry in response to the consistent interest in AI technologies include fostering collaboration to safeguard public health, promoting harmonisation of regulations, advancing regulatory approaches to encourage innovation, and supporting research for the evaluation and monitoring of AI technology performance.

Establishing a clear data boundary will also be essential for pharmaceutical manufacturers and their partners to understand and utilise the correct and specific data to optimise their processes. “To create reliable AI systems, you first need a deep understanding of the data and the regulations that govern it,” comments Purna Thakker, Founder and CEO of ADPT Solutions. “Only then can you build AI models that are accurate and easy to validate.”

Strategic sustainability

Collaborative strategies will also be evermore important for pharmaceutical companies looking to achieve their sustainability goals in 2025. Partnerships prioritising sustainability goals will affect the kinds of collaborations we will seen in the coming years. Given the complexities of measuring Scope 3 emissions, there is increasing pressure on pharmaceutical and biotech companies to account for the sustainability and emissions across their supply chain, including their contracted partners. Add on the beginning of sustainability policies implemented by local and international governing bodies and it is clear that companies throughout the pharma supply chain will have to be all the more aware of the sustainability credentials of all those they work with.

Want to learn more about which trends will shape the pharmaceutical supply chain in 2025? Download our 2025 Pharma Trends Outlook report here to stay informed.